Fundamental Analysis of TENAX THERAPEUTICS INC(NASDAQ:TENX) stock

Fundamental Rating

TENX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. TENX may be in some trouble as it scores bad on both profitability and health. TENX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TENX has reported negative net income.

In the past year TENX has reported a negative cash flow from operations.

TENX had negative earnings in each of the past 5 years.

TENX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TENX has a Return On Assets of -66.03%. This is in the lower half of the industry: TENX underperforms 62.56% of its industry peers.

TENX's Return On Equity of -95.28% is in line compared to the rest of the industry. TENX outperforms 46.50% of its industry peers.

		Industry Rank	Sector Rank
ROA	-66.03%
ROE	-95.28%
ROIC	N/A

ROA(3y)-313.86%

ROA(5y)-243.33%

ROE(3y)-538.22%

ROE(5y)-409.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TENX has less shares outstanding than it did 1 year ago.

TENX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for TENX has been reduced compared to a year ago.

2.2 Solvency

TENX has an Altman-Z score of -36.05. This is a bad value and indicates that TENX is not financially healthy and even has some risk of bankruptcy.

TENX's Altman-Z score of -36.05 is on the low side compared to the rest of the industry. TENX is outperformed by 92.48% of its industry peers.

TENX has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.06, TENX is doing worse than 62.56% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF	N/A
Altman-Z	-36.05

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

TENX has a Current Ratio of 3.26. This indicates that TENX is financially healthy and has no problem in meeting its short term obligations.

TENX's Current ratio of 3.26 is on the low side compared to the rest of the industry. TENX is outperformed by 63.42% of its industry peers.

A Quick Ratio of 3.26 indicates that TENX has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.26, TENX is doing worse than 62.22% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.26
Quick Ratio	3.26

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.63% over the past year.

EPS 1Y (TTM)76.63%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q90.62%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

TENX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.54% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y78.59%

EPS Next 2Y37.67%

EPS Next 3Y24.34%

EPS Next 5Y16.54%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TENX. In the last year negative earnings were reported.

Also next year TENX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TENX's earnings are expected to grow with 24.34% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.67%

EPS Next 3Y24.34%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TENX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TENAX THERAPEUTICS INC

NASDAQ:TENX (4/18/2024, 7:00:02 PM)

After market: 3.66 -0.02 (-0.54%)

3.68

+0.09 (+2.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.51M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.03%
ROE	-95.28%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.06
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.26
Quick Ratio	3.26
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)76.63%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y78.59%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

TENAX THERAPEUTICS INC (TENX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens